{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T06:15:05Z","timestamp":1778739305222,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2307601"],"award-info":[{"award-number":["2023YFC2307601"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.vaccine.2026.128575","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T16:14:17Z","timestamp":1776356057000},"page":"128575","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The immune response of the mRNA vaccine CS-2034 as a heterologous booster before and after breakthrough infection: A follow-up study"],"prefix":"10.1016","volume":"81","author":[{"given":"Jun-Dong","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi-Ling","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang-Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Qing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Yuan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7902","key":"10.1016\/j.vaccine.2026.128575_bb0005","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41586-022-04411-y","article-title":"Rapid epidemic expansion of the SARS-CoV-2 omicron variant in southern africa","volume":"603","author":"Viana","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.128575_bb0010","article-title":"SARS-CoV-2 omicron variant: Epidemiological features, Biological Characteristics, and Clinical Significance","volume":"13","author":"Guo","year":"2022","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128575_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.02.032","article-title":"The antigenic anatomy of SARS-CoV-2 receptor binding domain","volume":"184","author":"Dejnirattisai","year":"2021","journal-title":"Cell"},{"issue":"7821","key":"10.1016\/j.vaccine.2026.128575_bb0020","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","article-title":"Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike","volume":"584","author":"Liu","year":"2020","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.vaccine.2026.128575_bb0025","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the omicron (b.1.1.529) variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128575_bb0030","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41591-023-02648-2","article-title":"Author correction: real-world COVID-19 vaccine effectiveness against the omicron BA.2 variant in a SARS-CoV-2 infection-naive population","volume":"30","author":"Lau","year":"2024","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128575_bb0035","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128575_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10020272","article-title":"Post-vaccination SARS-CoV-2 infections among health workers at the University Hospital of Verona, Italy: a retrospective cohort survey","volume":"10","author":"Porru","year":"2022","journal-title":"Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128575_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.09.018","article-title":"Molecular architecture of the SARS-CoV-2 virus","volume":"183","author":"Yao","year":"2020","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128575_bb0050","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1002\/jmv.27697","article-title":"Current evidence on efficacy of COVID-19 booster dose vaccination against the omicron variant: a systematic review","volume":"94","author":"Chenchula","year":"2022","journal-title":"J Med Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128575_bb0055","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa2203965","article-title":"Effects of previous infection and vaccination on symptomatic omicron infections","volume":"387","author":"Altarawneh","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128575_bb0060","series-title":"COVID-19 advice for the public: Getting vaccinated [M]","author":"Orgniaztion","year":"2024"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128575_bb0065","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-41342-2","article-title":"Previous immunity shapes immune responses to SARS-CoV-2 booster vaccination and omicron breakthrough infection risk","volume":"14","author":"P\u00e9REZ-AL\u00f3S","year":"2023","journal-title":"Nat Commun"},{"issue":"91","key":"10.1016\/j.vaccine.2026.128575_bb0070","article-title":"Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 spike immunogen induces potent humoral and cellular immune responses","volume":"5","author":"Bos","year":"2020","journal-title":"NPJ Vaccines"},{"issue":"7830","key":"10.1016\/j.vaccine.2026.128575_bb0075","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"issue":"68","key":"10.1016\/j.vaccine.2026.128575_bb0080","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abn8014","article-title":"Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants","volume":"7","author":"Bates","year":"2022","journal-title":"Sci Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128575_bb0085","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1473-3099(23)00001-4","article-title":"Tracking immune correlates of protection for emerging SARS-CoV-2 variants","volume":"23","author":"Nilles","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128575_bb0090","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1473-3099(23)00199-8","article-title":"Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged \u226518 years: a randomised, double-blind, phase 2b trial","volume":"23","author":"Wu","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"50","key":"10.1016\/j.vaccine.2026.128575_bb0095","article-title":"SARS-CoV-2 RBD neutralizing antibody induction is enhanced by particulate vaccination","volume":"32","author":"Huang","year":"2020","journal-title":"Advanced materials (Deerfield Beach, Fla)"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128575_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2023.101305","article-title":"A broadly reactive antibody targeting the n-terminal domain of SARS-CoV-2 spike confers fc-mediated protection","volume":"4","author":"Adams","year":"2023","journal-title":"Cell reports Medicine"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128575_bb0105","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01814-21","article-title":"Neutralizing monoclonal antibodies inhibit SARS-CoV-2 infection through blocking membrane fusion","volume":"10","author":"Li","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128575_bb0110","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2316422","article-title":"Neutralizing antibody titers over 12 months after SARS-CoV-2 mRNA vaccine booster in patients with relapsing multiple sclerosis continuously treated with ofatumumab","volume":"20","author":"Ziemssen","year":"2024","journal-title":"Hum Vaccin Immunother"},{"issue":"6576","key":"10.1016\/j.vaccine.2026.128575_bb0115","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science (New York, NY)"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128575_bb0120","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128575_bb0125","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/S2666-5247(21)00267-6","article-title":"Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis","volume":"3","author":"Cromer","year":"2022","journal-title":"Lancet Microbe"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128575_bb0130","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/S2213-2600(21)00456-2","article-title":"Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers","volume":"9","author":"Tober-Lau","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128575_bb0135","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/eji.202149758","article-title":"Neutralizing antibody responses 300 days after SARS-CoV-2 infection and induction of high antibody titers after vaccination","volume":"52","author":"Urlaub","year":"2022","journal-title":"Eur J Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2600383X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2600383X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:48:35Z","timestamp":1778737715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2600383X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":27,"alternative-id":["S0264410X2600383X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128575","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The immune response of the mRNA vaccine CS-2034 as a heterologous booster before and after breakthrough infection: A follow-up study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128575","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128575"}}